Brazil Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Report 2022 to 2030

Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

Brazil's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $93 Mn in 2022 to $216 Mn in 2030 with a CAGR of 11.20% for the year 2022-30. The expansion of the PNH therapeutics market in Brazil is anticipated to be fueled by the creation of new technologies and treatment options for PNH. For instance, the recent approval of eculizumab (a monoclonal antibody that targets the complement system for the treatment of PNH) has dramatically improved patient outcomes and is probably going to lead to a rise in the demand for PNH medicines in Brazil. The market is segmented by therapy, diagnostic test, and distribution channel. Some key players in this market include Aché Laboratórios, Eurofarma, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, and Bioverativ.

ID: IN10BRPH312 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Jigyasu Bhandari

Buy Now

Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

Brazil's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $93 Mn in 2022 to $216 Mn in 2030 with a CAGR of 11.20% for the year 2022-30. Brazil's current health expenditures climbed (as a percentage of GDP) from 9.59% in 2019 to 10.68% in 2023. By 2040, Brazil's health expenditures will account for 12.6% of its GDP, with opportunities for expansion in sectors including basic care, hospital care, pharmaceuticals, long-term care, and administration. Brazil has a male life expectancy of 72.5 years and a female life expectancy of 79.5 years. Brazil's population is growing by 0.7% annually.

In Brazil, a rare blood condition known as Paroxysmal Nocturnal Hemoglobinuria (PNH) can affect people of any age, race, or gender. A PIGA gene mutation that results in the formation of defective red blood cells that are prone to early destruction (hemolysis) is what causes PNH. Hematologists and other experts with training in the diagnosis and treatment of blood diseases are often in charge of managing PNH in Brazil. Blood transfusions, immunosuppressive therapy, and anticoagulant therapy are a few possible PNH treatments. Due to PNH's rarity, there aren't many specialized facilities in Brazil that can handle this ailment. However, there are numerous hospitals and medical facilities across the nation that provide specialized care for patients with PNH.

brazil-paroxysmal-nocturnal-hemoglobinuria-therapeutics-market

Market Dynamics

Market Growth Drivers

The expansion of the PNH therapeutics market in Brazil is anticipated to be fueled by the creation of new technologies and treatment options for PNH. For instance, the recent approval of eculizumab (a monoclonal antibody that targets the complement system for the treatment of PNH) has dramatically improved patient outcomes and is probably going to lead to a rise in the demand for PNH medicines in Brazil. Recent increases in healthcare spending by the Brazilian government are anticipated to boost access to PNH medicines and other specialized therapies for uncommon diseases. PNH therapies are projected to see a rise in demand as healthcare professionals and patients in Brazil become more aware of PNH.

Market Restraints

There aren't many specialized facilities in Brazil that can handle PNH because it's a rare ailment. Accessing the care and treatment patients require may become challenging as a result. Even though PNH is becoming more well-known in Brazil, many patients might not yet be aware of the condition or the range of potential therapies. Delays in diagnosis and treatment may result from this, which could harm the course of the patient's recovery. Patients may find it challenging to get PNH medications because their costs can be too high. In Brazil, where there is a sizable population of low-income people who might not have access to health insurance or other forms of financial help, this is particularly difficult.

Competitive Landscape

Key Players

Aché Laboratórios (BR)
Eurofarma (BR)
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The pharmaceutical sector in Brazil is governed by the ANVISA or Brazilian Health Regulatory Agency. It is in charge of overseeing the procedure for new medications getting approved, including those used to treat PNH. The national healthcare system in Brazil is referred to as SUS or the Brazilian Unified Health System. All Brazilian citizens are given access to free healthcare services, including access to medications. In Brazil, the SUS is crucial to the provision of PNH medications. A patent system is in effect in Brazil to protect novel medications and technologies. The country's access to and cost of PNH treatments are impacted by this system. The cost of drugs is governed in Brazil by the government. This could affect both the availability of PNH treatments in Brazil as well as the profitability of pharmaceutical firms doing business there. Clinical studies for novel medications in Brazil require ANVISA approval. This may affect the cost and pace of new PNH therapy development in the nation.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.